Several small GTPases of the Ras superfamily have been shown to antagonize TGFb signaling in human tumor cell lines. Some of these GTPases are post-translationally modi®ed by farnesylation, a lipid modi®cation catalyzed by farnesyltransferase and required for the proteins to attach to membranes and to function. In this study, we investigated the eect of the farnesyltransferase inhibitor FTI-277 on TGFb-regulated cell growth and transcription. Treatment of the human pancreatic tumor cell line, Panc-1, with FTI-277 enhanced the ability of TGFb to inhibit both anchorage-dependent and -independent tumor cell growth. FTI-277 also enhanced the ability of TGFb to induce transcription, as measured by p3TP-lux reporter activity and collagen synthesis. 
Introduction
Transforming growth factor beta (TGFb) is the prototype of a family of structurally related cytokines capable of inducing diverse cellular responses, including apoptosis, dierentiation, and cell cycle arrest (Kingsley, 1994; Sporn and Roberts, 1990) . The loss of responsiveness to TGFb antiproliferative eects results in unrestrained cell growth and correlates with the malignant progression of several tumors, including breast carcinomas, hepatomas, gastric colon carcinomas, skin tumors, as well as B and T lymphomas (Hata et al., 1998; Markowitz and Roberts, 1996; Moskaluk and Kern, 1996; Taipale et al., 1998) . TGFb signals through sequential activation of two cell-surface receptor serine-threonine kinases, which phosphorylate Smad2 and/or Smad3 (Liu et al., 1997; Macias-Silva et al., 1996; Souchelnytskyi et al., 1997; Zhang et al., 1996) . Phosphorylated Smad2 or Smad3, together with Smad4, translocates into the nucleus and associates with other transcription factors, leading to the activation of transcription of speci®c genes Labbe et al., 1998; Lagna et al., 1996; Liu et al., 1997; Macias-Silva et al., 1996; Zhang et al., 1998; Zhou et al., 1998) .
Several studies have implicated small GTPases in TGFb signaling. For instance, microinjection of oncogenic H-Ras protein was shown to overcome the growth inhibition mediated by TGFb and, conversely, TGFb decreased the GTP-bound form of Ras (Howe et al., 1993) . Similarly, TGFb partially antagonized transformed phenotypes caused by Ras transformation (Serra et al., 1992) . Recent reports have shed light onto the regulatory crosstalk between TGFb/Smads and Ras/MAP kinase pathway, by demonstrating the involvement of the Ras/Raf pathway in Smad phosphorylation, which lead to the retention of Smads in the cytoplasm and thus, inactivation of TGFb signaling (Hartsough and Mulder, 1997; Hu et al., 1999; Kretzschmar et al., 1999; Mulder, 2000) . Another small GTPase, RhoB, of the Ras superfamily has been shown to antagonize TGFb-induced transcription (Engel et al., 1998) . RhoB is an immediate-early inducible gene, the expression of which is activated by genotoxic stress as well as by growth factors (Fritz et al., 1995; Jahner and Hunter, 1991) .
Small GTPases of the Ras superfamily are posttranslationally prenylated at their CAAX motif at the C terminus (Casey and Seabra, 1996; Marshall, 1993) . Protein prenylation involves addition of C15 (farnesyl) by farnesyltransferase (FTase) or C20 (geranylgeranyl) by geranylgeranyltransferase type I (GGTase-I) to the C-terminal cysteine residue of Ras and Rho and is critical for proper membrane localization and function (Casey and Seabra, 1996; Marshall, 1993) . H-Ras, K-Ras and N-Ras are exclusively farnesylated . However, RhoB is both farnesylated and geranylgeranylated in cells (Lebowitz et al., 1997) . Furthermore, K-Ras and N-Ras were found to be geranylgeranylated when human tumors were treated with farnesyltransferase inhibitors (Whyte et al., 1997; Rowell et al., 1997) . It is unclear why two types of prenylation occur, but there are examples showing that a protein's function can be altered by switching prenylation type (Cox et al., 1992) .
Because Ras requires farnesylation for its malignant transformation, we and others have developed farnesyltransferase inhibitors as potential anticancer drugs (Cox et al., 1992; Gibbs et al., 1994; Lobell and Kohl, 1998; Sebti and Hamilton, 1997) . We have subsequently shown that inhibitors such as FTI-277 and FTI-2153, potently inhibit oncogenic Ras signaling and human tumor growth in nude mice (Lerner et al., 1995; Sun et al., 1995 Sun et al., , 1998 . The potential for the use of FTIs in cancer chemotherapy is highlighted by studies in which administration of FTIs to mice bearing tumors, resulting from expression of an oncogenic H-Ras transgene, led to tumor regression (Barrington et al., 1998; Kohl et al., 1995; Mangues et al., 1998; Omer et al., 2000) . Presently, several structurally dierent FTIs are in human clinical trials.
We sought to determine whether FTIs could restore the growth inhibitory function of TGFb in tumor cells. We found TGFb-mediated inhibition of cell growth and transformation to be strongly enhanced by FTI-277. The stimulation of TGFb's antiproliferative eect by FTI-277 correlated with an increase in TGFb type II receptor expression resulting in increased TGFb binding to its receptor and stimulating transcription. These results demonstrate the involvement of farnesyltransferase activity in TGFb1 signaling and suggest that FTI-277 could be used to increase the responsiveness of some cancer cells to TGFb1.
Results
The farnesyltransferase inhibitor, FTI-277, enhances the ability of TGFb1 to inhibit Panc-1 tumor cell growth and transformation Small GTPases such as K-Ras, H-Ras and RhoB antagonize TGFb signaling and require farnesylation to function. To determine whether inhibition of FTase could restore the responsiveness of cancer cells to TGFb, we have treated the human pancreatic carcinoma, Panc-1 cells, which are weakly sensitive to TGFb1, with the FTase inhibitor FTI-277 in the presence or absence of TGFb1. The growth of Panc-1 cells was subsequently measured in both plastic (anchorage-dependent) and soft agar (anchorage-independent). Cells were plated in 96-well plates and treated with vehicle (DMSO) or FTI-277 (15 mM) and/or TGFb1 (400 pM). The inhibition of cell growth was assessed by MTT assay 72 h post-treatment as described in Materials and methods. While FTI-277 (15 mM) and TGFb1 (400 pM) individually inhibited cell growth by only 20%, co-treatment with FTI-277 and TGFb1 resulted in 75% cell growth inhibition (Figure 1 ). These results demonstrate that FTI-277 enhances the ability of TGFb1 to inhibit anchoragedependent cell growth of Panc-1 cells.
Using Panc-1 cells, we also assessed the ability of FTI-277 to enhance TGFb inhibition of transformation in a soft agar assay. Cells were plated in 12-well plates, treated with vehicle (DMSO) or FTI-277 (15 mM) and/ or TGFb (400 pM) as described under Materials and methods. Figure 2 shows that vehicle treated Panc-1 cells formed an average of 713+106 soft agar colonies. FTI-277 and TGFb1 treatment alone resulted in 442+53 and 556+97 colonies, respectively; whereas co-treatment caused a much larger decrease in colony formation (192+25). Thus, colony formation on soft agar was inhibited by 22% when cells were treated with TGFb1 and 38% when treated with FTI-277. However, co-treatment of Panc-1 cells with both TGFb1 (400 pM) and FTI-277 (15 mM) resulted in a strong inhibition (73%) of cell growth.
FTI-277 stimulates TGFb1-induced transcription
The results presented in Figures 1 and 2 demonstrate that FTI-277 cooperates with TGFb1 to inhibit cell growth and transformation. Since TGFb1 controls cell growth by regulating, at least in part, gene expression, we determined whether FTI-277 aects TGFb1-induced transcription. For this purpose we used the p3TP-Lux reporter, which is widely used to evaluate TGFb1 responsiveness in transient transfection assays Engel et al., 1998; Wrana et al., 1992) . The p3TP-Lux reporter contains three repeats of the TPA-Responsive Element (TRE) fused to a portion of the plasminogen activator inhibitor (PAI-1) promoter (Wrana et al., 1992) . Panc-1 cells were transiently transfected with p3TPLux as described under Materials and methods. Cells were treated with FTI-277 (15 mM) or vehicle (DMSO) and/or TGFb1 (200 pM) 15 h posttransfection, and the incubation was resumed for 24 h. Cell lysates were then assayed for luciferase activity and b-galactosidase activity as internal control for transfection eciency. The treatment of Panc-1 cells with TGFb1 resulted in an eightfold stimulation of transcription as measured by p3TP-Lux ( Figure 3A) . FTI-277 alone had no signi®cant eect on p3TP-Lux reporter activity. In contrast, p3TP-Lux transcriptional activity was stimulated by 18-fold when cells were cotreated with both FTI-277 and TGFb1. To demonstrate that FTI-277 inhibited FTase activity in Panc-1 cells under these conditions, the cell lysates from FTI- Figure 1 TGFb1-mediated inhibition of anchorage-dependent cell growth is enhanced by the farnesyltransferase inhibitor FTI-277. Panc-1 cells were incubated with 15 mM FTI-277 or vehicle (DMSO) and/or TGFb1 (400 pM) for 72 h. Cell growth was measured by MTT assay as described in Materials and methods. Data is presented as average+s.d. from three independent experiments 277-and TGFb1-treated samples were fractionated by SDS ± PAGE followed by immunoblotting with antiLaminB and anti-Rap1A antibodies ( Figure 3B ). LaminB is a farnesylated protein whereas Rap1A is a geranylgeranylated protein. In FTI-277-treated samples (lanes 2 and 4) LaminB farnesylation was inhibited whereas Rap1A geranylgeranylation was not (unprenylated proteins migrate slower in SDS ± PAGE gel). TGFb1 alone (lane 3) did not aect LaminB farnesylation or Rap1A geranylgeranylation.
The results presented in Figure 3A demonstrate that inhibition of protein farnesylation enhances TGFb1-induced transcription. Therefore, we next investigated whether FTI-277 aects the ability of transcription factors to bind to TGFb-responsive elements. For these experiments, we performed electrophoretic mobility shift assays (EMSA) with nuclear extracts from TGFb1 (200 pM) and/or FTI-277 (15 mM) -treated samples. Oligonucleotides containing a TGFb1-responsive sequence (TRE) (Wrana et al., 1992) , which contains an AP1-binding site, were used as probes. As shown in Figure 3C , TGFb1 induced the formation of a protein/ DNA complex (compare lanes 5 and 3, 3.8-fold increase). The formation of this complex was speci®c since it could be displaced by a 100-fold molar excess of unlabeled wild type (lane 1), but not with a 100-fold molar excess of the unlabeled mutated TRE oligonucleotide (lane 2). The binding of the complex to the TRE sequence was not aected by FTI-277 alone (compare lanes 4 and 3, 1.1-fold increase). However, the level of TRE-bound complex markedly increased in response to FTI-277 and TGFb1 co-treatment (lane 6, (B) FTI-277 inhibits Lamin B farnesylation but not Rap1A geranylgeranylation. Cell lysates from experiment (A) above were analysed by SDS ± PAGE followed by immunoblotting with an anti-Lamin B or anti-Rap1A antibody. Lamin B is a substrate for farnesyltransferase and thus, its farnesylation was inhibited by FTI-277 (lanes 2 and 4). However, FTI-277 had no eect on Rap1A (lanes 2 and 4), which is a substrate for geranylgeranyltransferase I. U for unprenylated and P for prenylated form. (C) Nuclear extracts (NE) from FTI-277-and TGFb1-treated samples were used in EMSA to determine the status of nuclear complexes that bound TRE sequence, similar to that present in p3TP-Lux reporter. The binding reactions contained NE from vehicletreated samples and either 1006 of wild type competitor, TRE (lane 1) or 1006 of an unrelated oligonucleotide (lane 2). In addition to NE from speci®c samples, as indicated on top of the ®gure, the binding reactions contained either a normal rabbit antibody (lanes 3 ± 6) or an anti-AP1 antibody (lanes 7 ± 10). Note, cotreatment of cells with both FTI-277 and TGFb led to a higher level of TRE-bound complexes (lane 6) that were supershifted with an anti-AP1 antibody (lane 10). Data is representative of four independent experiments 8.6-fold increase). In order to con®rm the identity of the nuclear protein in the TRE complex we used anti-AP1 antibodies. As can be seen in lanes 7 ± 10, the complex was supershifted by Ap-1 antibody. This eect was highly speci®c since antibodies to Sp1, Sp3, Smad2, Smad3 and Smad4 did not supershift the TRE-bound complex (data not shown). Altogether, these results demonstrate the ability of FTI-277 to selectively stimulate TGFb1-induced transcription as measured by p3TP-Lux reporter activity and the binding of transcription factors to TRE sequences.
To further characterize the eect of FTI-277 on TGFb1 responses, we examined whether TGFb1-induced collagen synthesis could be aected by FTI-277. NIH3T3 cells were treated with TGFb1 in the presence or absence of FTI-277 for 48 h prior to incubation with [ We next determined the optimal incubation time and concentration of FTI-277 required to enhance TGFb1-induced transcription. To this end, Panc-1 cells were transiently transfected with p3TP-Lux reporter and treated with FTI-277 (15 mM) and TGFb1 (100 pM) for 0, 7, 16 or 24 h ( Figure 5A ). Cell lysates were assayed for luciferase and b-galactosidase activity as described in Materials and methods. TGFb1 stimulated p3TP-Lux transcriptional activity by sixfold after 7 h of incubation and this stimulation was maintained at the same level (sixfold) at 16 and 24 h ( Figure 5A ). Co-treatment of cells with FTI-277 and TGFb1 for 7 h did not further enhance p3TP-Lux activity compared to TGFb1 treatment alone. However, when cells were incubated with both FTI-277 and TGFb1 for 16 and 24 h, p3TP-Lux transcriptional activity was enhanced by 18-and 16-fold respectively, as compared to sixfold with TGFb1 alone. To determine the minimum concentration of FTI-277 required for the enhancement of TGFb1-induced transcription, Panc-1 cells were transiently transfected with p3TP-Lux, treated with various concentrations of FTI-277 (0 ± 15 mM) and a constant concentration of TGFb1 (200 pM) for 16 h. In the absence of FTI-277, TGFb1 induced transcription by eightfold ( Figure 5B ). However, co-treatment of cells with TGFb1 and 1, 5, 10 or 15 mM FTI-277 resulted in 12-, 14-, 15-and 14-fold stimulation of transcription, respectively. Thus, FTI-277 stimulates the ability of TGFb1 to induce transcription with a concentration as low as 1 mM FTI-277, but this stimulation requires a treatment period greater than 7 h.
The effect of FTI-277 on TGFb1-induced transcription is cell type specific A previous study reported that farnesyltransferase inhibitors have little eects on TGFb1-induced transcription in Mv1Lu (Mink lung epithelial cells), a cell line that is commonly used to assess TGFb1 responsiveness (Ventura et al., 1996) . The discrepancy between our results and the one previously reported could be due to dierences in cell lines used, suggesting a cell type speci®c eect. Therefore, we evaluated the eect of FTI-277 on TGFb1-induced transcription in various cell lines including Mv1Lu, A-549 (a human lung adenocarcinoma), C-33A (a human cervical carcinoma), MiaPaCa (a human pancreatic carcinoma), and NIH3T3 cells. The cell lines were transfected with p3TP-Lux and cell lysates were prepared and assayed for luciferase activity. In the absence of FTI-277, TGFb1 (200 pM) stimulated p3TP-Lux transcriptional activity by an average of 6.9-fold in Panc-1, 7.2-fold in A-549, 10-fold in NIH3T3, 13.3-fold in Mv1Lu, 1.1-fold in C-33A and 1.1-fold in MiaPaCa (Table 1) . In contrast, in the presence of FTI-277 (15 mM), TGFb1-induced transcription was strongly enhanced in Panc-1 (17.7 vs 6.9), A-549 (11 vs 7.2) and NIH3T3 (23.6 vs 10.0). However, in Mv1Lu cells, TGFb1-induced transcription was not enhanced by FTI-277, but rather slightly repressed (10.1 vs 13.3), in agreement with the previously reported results (Ventura et al., 1996) . C-33A and MiaPaCa cell lines, which are de®cient in TGFb typeII receptor and Smad4, respectively, did not respond to TGFb1 nor to the co-treatment with FTI-277. Thus, enhancement of TGFb1-induced transcription by FTI-277 is cell type dependent and necessitates a functional TGFb1-signaling pathway.
TGFb type II receptor level is increased following inhibition of farnesyltransferase
The results described above clearly show that in cell lines that possess functional TGFb signaling, FTI-277 strongly enhances the responsiveness to TGFb1 as measured by transcription induction and tumor cell growth inhibition. TGFb mediates its eect by binding to the type II receptor (TbRII) at the cell surface, which subsequently recruits and activates the type I receptor (TbRI). To determine whether FTI-277 treatment increases TGFb receptor levels, we treated Panc-1 cells with FTI-277 (15 mM) for 24 h and analysed by immunohistochemistry the endogenous level of TGFb type I and II receptors ( Figure 6A ). The level of TbRI was not aected by FTI-277-treatment, whereas the TbRII level was signi®cantly increased in FTI-277-treated cells. To determine whether the increase in the TbRII level could be due to elevated TBRII transcription, HaCat cells were transfected with the p1233-Luc reporter, which carries the TbRII promoter upstream of the luciferase gene, in the presence or absence of FTI-277. The promoter activity of TbRII was stimulated by fourfold in response to FTI-277 ( Figure 6C ). Due to the increased expression of TbRII in response to FTI-277, it was of interest to determine whether the binding of TGFb1 ligand to TbRII was aected by FTI-277 treatment. To this end, Panc-1 cells were treated with vehicle (DMSO) or FTI-277 (15 mM) for 48 h prior to incubation with 125 I-TGFb1 as described in Materials and methods. The 125 I-TGFb1-receptor complexes were cross-linked with dissuccinimydil suberate (Centrella et al., 1995) , extracted, and fractionated by electrophoresis in a 5 ± 10% gradient polyacrylamide gel ( Figure  6B ). The level of TbRII is increased. Taken together, these results show that FTI-277 stimulates TbRII transcription leading to increased levels of TbRII, and increased binding of TGFb1 ligand to the receptor. Furthermore, this eect is independent of Ras mutation status and whether the cell line is transformed or non-transformed, since Panc-1 is a cancer cell line with a K-Ras mutation whereas HaCat is a normal cell with wild type Ras.
Discussion
Resistance to TGFb occurs frequently in solid tumors of epithelial origin and contributes to the uncontrolled growth of these tumors (Jennings and Pietenpol, 1998; Kim et al., 1999; Markowitz and Roberts, 1996; Reiss, 1999) . Although mutation of the receptors contributes to TGFb resistance, deregulation of TGFb signaling cascades represents an equally important mechanism underlying TGFb resistance (Hartsough and Mulder, 1997) . A number of reports clearly show the existence of an interaction between small GTPases and TGFb pathways. For instance, overexpression of H-ras or KRas oncogenes in epithelial cells leads to escape from the growth-inhibitory action of TGFb due to alteration in TGFb receptors (Coppa et al., 1997; Filmus et al., 1992; Zhao and Buick, 1995) . Restored expression of TGFb type II receptor in K-Ras-transformed thyroid cells reverted their malignant phenotype (Coppa et al., 1997; Turco et al., 1999) . In a skin tumor model, cells expressing activated Ras escaped from TGFb control (Missero et al., 1991; Sipes et al., 1990) . Conversely, TGFb was also capable of partially suppressing the transformed phenotype of Ras-transformed hepatocytes (Serra et al., 1992) . Furthermore, the function of Rac1 and RhoA proteins was shown to be required for TGFb to transduce its signal Mucsi et al., 1996) , and RhoB protein was stabilized in TGFb-treated cells (Engel et al., 1998) .
Several small GTPases such as H-Ras, N-Ras, KRas and RhoB, are modi®ed by farnesylation. Inhibition of farnesylation by FTIs was shown to inhibit the growth of Ras-and non Ras-transformed cells and lead to complete tumor regression in mice expressing oncogenic transgenes (Kohl, 1999; Lebowitz and Prendergast, 1998; Norgaard et al., 1999; Oli, 1999; Rowinsky et al., 1999; Sebti and Hamilton, 1997) . To determine whether FTIs could aect TGFb function, we analysed the growth of human pancreatic carcinoma cells, Panc-1, which are weakly sensitive to TGFb, in response to FTI-277 and TGFb. We found FTI-277 to strongly enhance the ability of TGFb to inhibit anchorage-dependent and -independent cell growth and activate transcription. The ability of FTI-277 to enhance TGFb-induced transcription was not unique to Panc-1 cells in that it also occurred in the human lung tumor cell line, A-549, as well as mouse NIH3T3 ®broblasts. A previous study showed that treatment of Mv1Lu mink lung epithelial cells with the FTI L-744-832 either had no eect or actually inhibited (at high concentrations) TGFb-mediated transcription (Ventura et al., 1996) . In agreement with this report, FTI-277 slightly decreased TGFb-induced transcription in Mv1Lu cells. Therefore, the eect of FTI-277 on TGFb signaling is cell-type speci®c. The reason for this cell type speci®city is not clear at present. Analysis of the eect of FTI-277 on TGFb responsiveness in a broad spectrum of human tumor cell lines with known genetic alterations may suggest a reason for this speci®city. For example, cell lines that lack components of the TGFb signaling pathway, such as TbRII (C-33A) or Smad4 (MiaPaCa), as expected do not respond to TGFb. More importantly, FTI-277 did not sensitize these cells to TGFb, suggesting that a functional TGFb signaling pathway is required for FTI-277 to aect TGFb signaling. The stimulation of TGFb's antiproliferative eect by FTI-277 correlated with an increase of the level of TbRII gene transcription and protein expression that led to higher levels of TGFb binding to its receptor, TbRII. Thus, FTI-277, by increasing TbRII levels, would enable more cells to be arrested by TGFb. Panc-1 cells express oncogenic K-Ras, which was shown to become geranylgeranylated when farnesyltransferase is inhibited (Lerner et al., 1997; Rowell et al., 1997; Whyte et al., 1997) . Thus, it is unlikely that the sensitization to TGFb was due to inhibition of K-Ras farnesylation since both farnesyltransferase and geranylgeranyltransferase I need to be inhibited in order to inhibit K-Ras prenylation and function. However, we cannot rule out that geranylgeranylated K-Ras, which is accumulated in cells treated with FTI, may sensitize cells to TGFb. H-Ras and NRas, although present in wild type forms in these cells, could be targets for FTI-mediated enhancement of TGFb signaling. Recently, several reports pointed to a role for Ras proteins in the regulation of Smads nuclear accumulation. Whereas receptor-mediated phosphorylation of Smads at C-terminal sites activates Smads (Kretzschmar et al., 1997b; Macias-Silva et al., 1996) , extracellular signal-regulated kinase (ERK) mediated phosphorylation, in response to activators of the Ras/MAPK pathway, inhibit Smads accumulation in the nucleus (Kretzschmar et al., 1997a (Kretzschmar et al., , 1999 Mulder, 2000; Yue et al., 1999) . In colon cancer, it was proposed that inhibition of Smad2/3 nuclear translocation by a hyperactive Ras pathway prevents TGFb antiproliferative responses (Calonge and Massague, 1999) . Therefore, it is possible that FTI-277, by inhibiting the farnesylation of Ras and other proteins, allows for increased nuclear accumulation of Smads and thus, a stronger TGFb response. Alternatively, and consistent with our results, FTI-277 could also antagonize the ability of Ras and other farnesylated proteins to suppress TGFb type II receptor expression.
Materials and methods

Plasmid constructs
The p3TP-Lux luciferase reporter construct was a gift from J MassagueÂ (Sloan Kettering Cancer Center, New York, NY, USA). p3TP-Lux contains three repeats of the TPAresponsive element fused to a portion of the PAI-1 promoter. The p1233-Luc reporter construct contains the TGFb type II receptor gene promoter as described previously (MunozAntonia et al., 1996) .
Tissue culture and transfection
The human pancreatic carcinoma-derived cell lines MiaPaCa and Panc-1 and the human cervical carcinoma cell line C-33A were grown in Dulbecco's Modi®ed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The human lung carcinoma-derived cell line A549 (ATCC) was grown in F12 medium supplemented with 10% FBS. The mink lung epithelial cell line Mv1Lu (CCL64, ATCC) was grown in minimal essential medium (MEM) supplemented with 10% FBS. The mouse ®broblastic cell line NIH3T3 was grown in DMEM supplemented with 10% calf serum (CS). The cell lines were cotransfected with 2 mg of p3TP-Lux reporter construct and 0.5 mg of pCMV-bgal, as an internal control for transfection eciency, using a modi®ed calcium phosphate co-precipitation method (Adnane et al., 1998) . Fifteen hours post-transfection, the medium was replaced with fresh medium supplemented with 0.5% FBS containing a farnesyltransferase inhibitor, or vehicle (DMSO) and TGFb1 (R&D Systems). The cells were lysed and aliquots of cell lysates were analysed for b-galactosidase and luciferase activity. The luciferase activity was determined using the Luciferase Assay System (Promega). The samples were normalized for transfection eciency against bgalactosidase activity. The fold induction was calculated by dividing the luciferase activity values of FTI-277-or TGFb1-treated samples by that of vehicle-treated control.
Inhibition of protein farnesylation
The ecacy of FTI-277 to inhibit protein farnesylation was veri®ed by analysing the status of Lamin B farnesylation in the cell lysate, as described previously (Lerner et al., 1997) . Brie¯y, aliquots of cell lysate were analysed by SDS ± PAGE followed by immunoblotting with anti-Lamin B antibody or, as control, anti-Rap1A antibody (sc-6216, sc-1482, respectively, SantaCruz Biotechnology). Lamin B serves as a positive control for the eect of FTI-277 since it is known to be strictly farnesylated, while Rap1A serves as a negative control since it is only geranylgeranylated.
MTT assay
Cell growth was measured by MTT [3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Carmichael et al., 1987) . Brie¯y, cells were seeded at 10 3 cells per well in 96-well culture plates in quadruplicate. The following day, the medium was changed to DMEM supplemented with 10% FBS containing various concentrations of FTI-277, and/or TGFb1 for 48 or 72 h. Subsequently, the medium was removed and the cells were incubated with 180 ml of DMEM containing 10% FBS and 0.25 mg/ml MTT (Sigma) at 378C for 3 h, followed by solubilization with DMSO for 5 min. The absorbance of each well was measured with a microplate reader at 570 nm. The number of viable cells is proportional to the absorbance.
Soft agar colony formation assay
This assay was performed as previously described (Lerner et al., 1997) . Brie¯y, 500 ml of 0.5% NuSieve agarose in DMEM containing 10% FBS was used to coat the bottom of each well in 12-well culture dishes. 2.5610 2 cells were suspended in 500 ml of DMEM supplemented with 10% FBS and 0.3% NuSieve agarose, then transferred to the precoated dishes. Where indicated, FTI-277 (15 mM) or TGFb1 (200 pM) was added to the agar mixture. Cells were fed twice weekly with growth medium containing FTI-277 (15 mM) and TGFb1 (200 pM). At the end of the incubation period, the culture dishes were stained and scanned, and the number of colonies counted.
I-TGFb1 binding assay
Panc-1 cells were plated in 6-well plates at a density of 1610 5 cells per well in DMEM supplemented with 10% FBS and permitted to attach for 16 h. The medium was replaced with DMEM supplemented with 0.5% FBS and vehicle (DMSO) or FTI-277 (15 mM) and incubation was resumed for 48 h. The binding of TGFb1 to TbR-II was performed for 3 h at 48C using 100 pM 125 I-TGFb1 (Biomedical Technolgies, Inc., Stoughton, MA, USA) as described previously (Centrella et al., 1995) . To crosslink 125 I-TGFb1-binding complexes, 0.2 mM dissuccinimydil suberate (Sigma) was added to the cells. The cell lysates were fractionated by electrophoresis in a 5 ± 10% gradient polyacrylamide gel. The 125 I-TGFb1-receptor complexes were visualized by a phosphorimaging system (Molecular Dynamics).
Immunohistochemical analysis
FTI-277 (15 mM, 48 h) or vehicle treated Panc-1 cells (1610 5 ) were centrifuged at 500 r.p.m. for 5 min using a Shandon Cytospin3 centrifuge. The slides were ®xed in 95% ethanol, rinsed in de-ionized water, placed in PBS for 5 min and drained. Blocking serum was applied and the slides were incubated in a humid chamber for 20 min at RT. The following primary antibodies were applied at RT at a 1 : 100 dilution: anti-TbR-II (C-terminal domain); and anti-TbR-I (sc-398, Santa Cruz Biotechnology). For detection, the Vectastain ABC Kit, Rabbit IgG, Elite series (Vector Laboratories, Inc., Burlingame, CA, USA) was used following the manufacturer's speci®cations. The biotinylated secondary antibody was applied for 20 min at RT in a humid chamber. The slides were rinsed, placed in PBS for 5 min, then incubated with the ABC complex for 30 min at RT. DAB, prepared following the manufacturer's recommendations, was applied to the slides and color development was monitored. After 2 ± 5 min the slides were rinsed in water, and counter-stained with modi®ed Mayer's hematoxylin for 30 s. The slides were rinsed with water, dehydrated, cleared, and mounted with resinous mounting medium.
Electrophoretic mobility shift assay TPA-responsive element TRE (5'-GGGATGAGTCAGA-CACCTCTGGCTTTCTGGAAGGGAGC-3') (Wrana et al., 1992) and mutant competitor (5'-GGTTATCTA-GAACTGGGTTATCTAGAACTGGGTTATCT-3') oligonucleotides were purchased from Gibco BRL. Two pmoles of annealed wild type oligonucleotides were end labeled with T4 kinase (Gibco BRL) and 50 mCi g-32 P-ATP. Nuclear extracts were prepared from FTI-277 and/or TGFb-treated Panc-1 cells as well as vehicle-treated cells. Cells were ®rst treated with FTI-277 (15 mM) for 24 h then TGFb1 was then added to the medium and the incubation was continued for 16 h. Cells were washed with cold PBS and then harvested in 1 ml of TEN buer (40 mM Tris (pH 7.5), 1 mM EDTA (pH 8.0), 150 mM NaCl). The cell pellet was resuspended in 60 ml of hypotonic buer A (10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM DTT, and 1 mM PMSF), transferred to a microfuge tube, and three cycles of freeze-thaw were performed. The nuclei were recovered by centrifugation for 1 min at full speed. The nuclei were resuspended in 20 ml of buer C (0.2 mM EDTA (pH 8.0), 20 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 420 mM KCl, 25% glycerol, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM DTT, and 1 mM PMSF) and incubated 30 min at 48C. The supernatants were clari®ed and protein concentrations were determined. Binding reactions were performed at RT. The ®nal volume of the binding reactions was 20 ml in which 6 mg of nuclear extract, 1 mg/ml poly (dI-dC), unlabeled speci®c competitor, 2 ml of 106 binding buer (100 mM Tris (pH 7.5), 50 mM EDTA (pH 8.0) 10 mM MgCl 2 , 10 mM DTT, 50% glycerol and 250 mM NaCl) were combined and incubated for 10 min at RT. Forty thousand c.p.m. of radiolabeled probe was added and the incubation was continued for 20 min at RT. For supershift assays, 1 ml of AP1 polyclonal antibody (sc-45X, SantaCruz Biotechnology) was added to the binding reaction and incubation was resumed for 30 min at RT. The binding reactions were resolved on 0.56 TBE, 5.0% acrylamide gel at 100 V for 4 h at RT. The gels were subsequently dried and exposed for autoradiograghy.
Collagen synthesis
Collagen synthesis was measured as described before (Centrella et al., 1991) . Brie¯y, NIH3T3 cells, grown in 6-well plates, were treated with either FTI-277 (15 mM) or vehicle and/or TGFb (200 pM) for 48 h. The cells were pulsed with 12.5 mCi/ml of 3 H-proline (NEN, Boston, MA) during the last 2 h of treatment. The cells were lysed by freezethawing, and extracted in 0.5% Triton X-100. The samples were precipitated with 10% TCA, and the amount of 3 Hproline incorporation into collagenase digestible and noncollagenase digestible material was measured using collagenase free of non-speci®c protease activity (Worthington Biochemicals). The per cent collagen synthesis was calculated after correcting for the relative abundance of proline in collagenase-digestible material.
